Constant vigilance: The role of pharmaceutical companies in medicine safety

Drug Information Journal

Volumn 43, Issue 5, 2009, Pages 603-616

  Dieck, Gretchen S ^a   Berger, Susan ^a   Kracov, Daniel A ^b   Manion, Dennis ^a   Tanner, Alun ^a  

^a PFIZER INC   (United States)

^b PLLC   (United States)

Author keywords

Benefit risk balance; FDAAA; Medicine safety; Pharmacovigilance signals; Risk management

Indexed keywords

DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; UNITED STATES;

EID: 70350168895     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300509     Document Type: Review

References (30)

1. Pfizer Drug Safety Stakeholder Research. November 2006. Adverse Events Reporting Survey Pfizer/Ipsos, March 2008. [Available upon request from correspondence author.]
2. Harris Interactive. Available at: http://www.harrisinteractive.com/news/ allnewsbydate.asp?NewsID=1206.
3. Council for International Organisations of Medical Sciences. Guidelines for Preparing Core Clinical-Safety Information on Drugs, Report of CIOMS Working Groups III and V, Geneva, 1998. See also: http://www.who-umc.org/DynPage. aspx7id=22684.
4. Pharmaceutical Industry Profile 2006, p. 4. Available at: http://www.phrma.org/files/2006%20Industry%20Profile.pdf.
5. Fetterman JE, Pines WL Nickel WK, Slatko GH. A Framework for Pharmaceutical Risk Management. Food and Drug Law Institute; 2003: 88.
6. Dreyer NA, Sheth N, Trontell A, Gliklich RE. Good practices for handling adverse events detected through patient registries. Drug Inf J. 2007;42:421-428.
7. Sutent Risk Management Plan. Available at: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/sutent/068706en6.pdf. See pp. 41-42.
8. Segal ES, Valette C, Oster L, et al. Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf. 2005;28:971-980. (Pubitemid 41483704)
9. EMEA. Tracleer, section 2.7.2. Available at: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/tracleer/EMEA-H-401-II-29-AR.pdf.
10. Thompson CA. Bosentan enters market with risk management program. Am J Health Syst Pharm. March 15, 2002. Available at: http://www.ashp.org/import/ News/HealthSystemPharmacyNews/newsarticle.aspx?id=901.
11. For FDA guidance to industry on the development and use of RiskMAPs, see: http://www.fda.gov/cder/guidance/6358fnl.htm#-Toc67721195. Note that FDA has indicated it plans to revise this guidance in light of the passage of FDAAA. For discussion of RiskMAPS, including evaluating their effectiveness, see Cobert B. Manual of Drug Safety and Pharmacovigilance. Jones and Bartlett, 2007: 71-74.
12. FDA Questions and Answers. Notice on drugs and biological products deemed to have risk evaluation and mitigation strategies. Federal Register. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FoodandDrugAdministrationAmendmentsActof2007.
13. Food and Drug Administration. REMS. Available at: http://www.fda.gov/ cber/genadmin/rems.htm.
14. Wechsler J. Manufacturers face new risk-management requirements. Pharm Tech. 2009; 33:26-32.
15. ClinPage. FDAAA update at DIA. July 8, 2008. Available at: http://www.clinpage.com/article/fdaaa-update-at-dia/.
16. Church RF. The clock moves backwards on FDA's drug review timelines: the impact of FDAAA, REMS and the lack of agency resources. Update. 2009; March/April: 10-13.
17. ICH website. Available at: http://www.ich.org/cache/compo/276-254-1.html.
18. Cobert B. Manual of Drug Safety and Pharmacovigilance. Jones and Bartlett, 2007: 41-52. See also: http://www.emea.europa.eu/pdfs/human/phv/ 11590605en.pdf.
19. Food and Drug Administration. Adverse Event Reporting System database. Available at: http://www.fda.gov/cder/aers/default.htm.
20. Hauben M, Aronson JK. Defining "signal" and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99-110.
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471. (Pubitemid 46919772)
22. Diamond GA, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147:578-581. (Pubitemid 351664507)
23. For a general description of pharmacoepidemiology, see: http://www.pharmacoepi.org/about/index.cfm.
24. For example, see: Hernández-Díaz S, García Rodríguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093-2099.
25. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;4:1006-1012.
26. Perrio M, Voss S, Shakir SA. Application of the Bradford Hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf. 2007;(30):333-346. (Pubitemid 46624532)
27. CDER Lecture Series, Pharmacogenomics From the Ground Up. Session 3, slide 8. Available at: http://www.fda.gov/cder/genomics/Concepts- Pharmacogenomics.pdf.
28. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391-396. (Pubitemid 47219454)
29. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14:567-572.
30. FDAAA. Available at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi? dbname=110-cong-public-laws&docid=f:publ085.110.